Journal Article

Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models

Brown, Peter, Poulsen, Christian Bjørn, Juul-Jensen, Karen, El-Galaly, Tarec Christoffer, Pedersen, Robert Schou, Jelicic, Jelena, Bukumiric, Zoran, Roost Clausen, Michael, Stauffer Larsen, Thomas, Ludvigsen Al-Mashhadi, Ahmed

2023

Overview

Currently, the International Prognostic Index (IPI) is the most used and reported model for prognostication in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). IPI-like variations have been proposed, but only a few have been validated in different populations (e.g., revised IPI (R-IPI), National Comprehensive Cancer Network IPI (NCCN-IPI)). We aimed to validate and compare different IPI-like variations to identify the model with the highest predictive accuracy for survival in newly diagnosed DLBCL patients. We included 5126 DLBCL patients treated with immunochemotherapy with available data required by 13 different prognostic models. All models could predict survival, but NCCN-IPI consistently provided high levels of accuracy. Moreover, we found similar 5-year overall survivals in the high-risk group (33.4%) compared to the original validation study of NCCN-IPI. Additionally, only one model incorporating albumin performed similarly well but did not outperform NCCN-IPI regarding discrimination (c-index 0.693). Poor fit, discrimination, and calibration were observed in models with only three risk groups and without age as a risk factor. In this extensive retrospective registry-based study comparing 13 prognostic models, we suggest that NCCN-IPI should be reported as the reference model along with IPI in newly diagnosed DLBCL patients until more accurate validated prognostic models for DLBCL become available.

• Publisher: Springer Nature B.V
• Subject: Chemotherapy / Immunotherapy / Lymphoma / Population-based studies / Validation studies